Overall, the studies discussed in this Section and in Section 7.1.3 provide evidence that a subgroup of T-ALL patients, displaying activation of the HH signaling pathway, may benefit from treatment with SMO or GLI1 inhibitors, alone or in combination with chemotherapy or other targeted therapeutics. The gene discussed is GLI1; the disease is acute lymphoblastic leukemia.